August 2025 : The US FDA approved Wegovy (semaglutide 2.4 mg) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced-calorie diet and increased physical activity
Its US licence is for people with a BMI of 30, considered obese, or a BMI of 27 with weight-related conditions, such as high blood pressure, type 2 diabetes or high cholesterol
Maximum recommended : 800 mcg daily Injection Best Practices: Use 27-31 gauge insulin syringes Rotate sites daily (abdomen, thigh, upper arm) Inject at 45-degree angle Let solution reach room temperature Wipe skin with alcohol, let dry completely Need help with reconstitution
Why are we a quality GLP-1 Booster Supplement manufacturer
Fabrican suplementos aptos para veganos o vegetarianos
(15% say theyre not sure)